Abstract Several previous reports suggested that many commercially available antibodies directed against G proteincoupled receptors (GPCR) lack sufficient selectivity. Accordingly, it has been proposed that receptor antibodies should be validated by at least one of several criteria, such as testing tissues or cells after knockout or silencing of the corresponding gene. Here, we tested whether 12 commercially available antibodies directed against α-adrenergic receptor (AR) subtypes (α 1A/B/D , α 2A/B/C ), atypical chemokine receptor 3 (ACKR3), and vasopressin receptor 1A (AVPR1A) suffice these criteria. We detected in flow cytometry experiments with human vascular smooth muscle cells that the fluorescence signals from each of these antibodies were reduced by 46 ± 10 %-91 ± 2 % in cells treated with commercially available small interfering RNA (siRNA) specific for each receptor, as compared with cells that were incubated with nontargeting siRNA. The tested antibodies included anti-ACKR3 (R&D Systems, mab42273), for which specificity has previously been demonstrated. Staining with this antibody resulted in 72 ± 5 % reduction of the fluorescence signal after ACKR3 siRNA treatment. Furthermore, staining with anti-α 1A -AR (Santa Cruz, sc1477) and anti-ACKR3 (Abcam, ab38089), which have previously been reported to be non-specific, resulted in 70 ± 19 % and 80 ± 4 % loss of the fluorescence signal after α 1A -AR and ACKR3 siRNA treatment, respectively. Our findings demonstrate that the tested antibodies show reasonable selectivity for their receptor target under our experimental conditions. Furthermore, our observations suggest that the selectivity of GPCR antibodies depends on the method for which the antibody is employed, the species from which cells/tissues are obtained, and on the type of specimens (cell, tissue/cell homogenate, or section) tested.
Introduction
G protein-coupled receptors (GPCR) or 7 transmembrane domain (7TM) receptors are the largest group of eukaryotic cell surface receptors and play important roles in physiology and pathology (Alexander et al. 2013; Venkatakrishnan et al. 2013; Vaidehi et al. 2014) . It has been estimated that approximately 50 % of all currently available drugs target GPCRs (Fredriksson and Schioth 2005) . Thus, selective antibodies that detect endogenous GPCRs can be essential for the study of these receptors (Gupta and Devi 2006; Talmont et al. 2012) . Several lines of evidence, however, suggested that many commercially available antibodies directed against GPCRs, such as histamine receptors, adrenoceptors, or chemokine receptors, lack sufficient selectivity (Hamdani and van der Velden 2009; Jensen et al. 2009; Pradidarcheep et al. 2009; Berahovich et al. 2010; Beermann et al. 2012; Bohmer et al. 2014; Cecyre et al. 2014; Cernecka et al. 2014; Talmont and Mouledous 2014) . Accordingly, it has been proposed that receptor antibodies should be validated by at least one of the following techniques: (a) disappearance of staining in knockout animals of the target receptor, (b) reduction of staining upon knockdown approaches such as small interfering RNA (siRNA) treatment, (c) selectivity of staining in immunoblots or immunocytochemistry for the target receptor vs. related subtypes when expressed in the same cell line, and/or (d) antibodies raised against multiple distinct epitopes of a receptor yielding very similar staining patterns ).
We have shown previously that several commercially available antibodies against chemokine (C-X-C motif) receptor 4 (CXCR4) show acceptable selectivity as we observed a major reduction of staining with these antibodies when endogenous CXCR4 was silenced with siRNA (Saini et al. 2010; Tripathi et al. 2015) . In the present study, we again applied these criteria and tested 12 commercially available antibodies directed against GPCR targets that are in the center of our current research interests: α-adrenoceptors, atypical chemokine receptor 3 (ACKR3), and vasopressin receptor 1A (AVPR1A). The tested antibodies included two antibodies that have previously been reported to be non-specific and an antibody that has been thoroughly evaluated and found to be specific for the GPCR target (Jensen et al. 2009; Berahovich et al. 2010 ).
Materials and methods
Cells and reagents Human aortic vascular smooth muscle cells (hVSMC) were obtained from the American Type Culture Collection (ATCC) and cultured as described in detail previously (Tripathi et al. 2015) . Antibodies were obtained from commercial sources and are listed in Table 1 . siRNA reagents were purchased from Thermo Scientific Dharmacon.
Gene silencing by RNA interference GPCR genes were silenced using commercially available siRNA, as described previously (Saini et al. 2010; Tripathi et al. 2015) . The siRNA that we used is listed in Table 1 . In brief, hVSMC were grown in 1 mL Accell siRNA delivery media per well (Thermo Scientific Dharmacon) in 12-well plates (Nunc). Accell siRNA was reconstituted with 1× siRNA buffer to a stock concentration of 100 μM. Cells were then transfected with 10 nmol siRNA and incubated for 72 h at 37°C, 5 % CO 2 . Accell non-targeting (NT) siRNA pool was used as negative control. After 72 h, cells were assayed for receptor cell surface expression by flow cytometry. For each receptor siRNA, we performed 3-8 independent transfections. From each transfection, cells were analyzed in duplicate by flow cytometry.
Flow cytometry Cells were labeled with primary antibodies (Table 1 , all antibodies were used in a 1:200 dilution) in combination with anti-rabbit FITC-conjugated goat IgG (ab6717, Abcam), anti-mouse FITC-conjugated goat IgG (ab6785), or anti-goat FITC-conjugated rabbit IgG (ab97104) diluted 1:70, as appropriate. Rabbit IgG (GWB-3274CD, R&D Systems) in combination with FITC-conjugated anti-rabbit goat IgG (ab6717, Abcam) was used as a negative control. The geometric fluorescence intensities of at least 3 × 10 4 cells were recorded and analyzed using the FlowJo software (Tree Star). All data are described as mean ± standard deviation.
Results
We compared the fluorescence signals of 12 commercially available antibodies directed against various GPCRs that were measured by flow cytometry using hVSMC after incubation with receptor-specific siRNA or non-targeting siRNA. All antibodies stained the cells (relative fluorescence units ( Figure 1 shows typical analyses of the fluorescence intensities for the antibodies directed against α 1 -AR subtypes (Fig.  1a) , α 2 -AR subtypes (Fig. 1b) , AVPR1A, and ACKR3 (Fig.  1c) . For α 1A -AR and α 1D -AR, two different antibodies were tested. The average reduction of the fluorescence signals for α 1 -AR subtype antibodies ranged from 62 ± 13 % for anti-α 1A -AR/ab137123 to 85 ± 3 % for anti-α 1D -AR/ sc27099 ( Fig. 1a and Table 1 ). The reduction of the fluorescence signals measured with α 2 -AR subtype antibodies was slightly lower than with α 1 -AR subtype antibodies and ranged from 46 ± 10 % for anti-α 2A -AR to 70 ± 20 % for anti-α 2C -AR ( Fig. 1b and Table 1 ). Figure 1c shows typical analyses of the fluorescence intensities for an antibody directed against AVPR1A and for three different antibodies directed against ACKR3. With anti-AVPR1A, we observed 91 ± 2 % reduction of the fluorescence signal after incubation of the cells with AVPR1A siRNA. When cells were incubated with ACKR3 siRNA, the fluorescence signals were reduced by 66 ± 4 % when cells were labeled with LS-B1815, and by 72 ± 5 % and 80 ± 4 % when cells were stained with mab42273 and ab38089, respectively, as compared with cells incubated with non-targeting siRNA (Table 1) .
As another selectivity control for the α 1 -AR subtype antibodies, we then incubated cells with non-targeting siRNA or siRNA for each α 1 -AR subtype and tested anti-α 1A -AR/ ab137123, anti-α 1B -AR/ab169523, and anti-α 1D -AR/ ab84402 for each condition by flow cytometry (Fig. 2a-c) . As shown in Table 2 , when cells were incubated with receptor-specific siRNA corresponding to the GPCR target of each antibody, the fluorescence signals were reduced by 68 ± 10 % after staining with anti-α 1A -AR/ab137123, and by 91 ± 3 % and 97 ± 1 % after staining with anti-α 1B -AR/ ab169523 (Fig. 2b) and anti-α 1D -AR/ab84402 (Fig. 2c) , respectively, as compared with cells incubated with nontargeting siRNA. The fluorescence intensities measured after incubation of cells with siRNA targeting other α 1 -AR subtypes, however, were comparable to the fluorescence signals from cells incubated with non-targeting siRNA for each antibody (Fig. 2a-c and Table 2 ). Furthermore, when cells were stained with anti-ACKR3/ab38089, the fluorescence signals were indistinguishable in cells incubated with α 1D -AR siRNA or non-targeting siRNA (Fig. 2d) .
Discussion
In the present study, we utilized hVSMC to evaluate selectivity of 12 commercially available antibodies directed against GPCR targets, which are known to be expressed in these cells (Alexander et al. 2013 ). Our results demonstrate that the tested GPCR antibodies reported with a major reduction of staining when hVSMC were transfected with the corresponding receptor-specific siRNA. According to criteria proposed by Michel et al., 
this constitutes reasonable evidence
for the specificity of the tested antibodies ). Previously, we have utilized the various α-AR subtype antibodies in proximity ligation assays with hVSMC and detected that these antibodies resulted in distinct signal patterns (Tripathi et al. 2015) . The finding of the present study that α 1 -AR subtype antibodies reported with a significant reduction of the fluorescence signals from flow cytometry experiments only when the corresponding receptor subtype gene was silenced with siRNA is in agreement with our previous observations and further indicates selectivity of the antibodies for their receptor targets Tripathi et al. 2015) .
Every antibody likely shows some degree of non-specific binding and siRNA gene silencing is not expected to fully abrogate expression of the target gene. Thus, the degree of reduction in staining that is required to confidently assume antibody selectivity could be a matter of debate. Anti-ACKR3 (mab42278, clone 11G8) has previously been validated for immunohistochemistry and flow cytometry utilizing the current gold standard, the use of tissues/cells in which the target gene is missing (Berahovich et al. 2010) . We Data are mean ± SD. (n) = sample size − number of transfections, in parentheses Ab antibody, pAb polyclonal antibody, mAb monoclonal antibody, WB Western blot, Flow Cyt flow cytometry, ICC immunocytochemistry, IF immunofluorescence, ELISA enzyme-linked immunosorbent assay, IHC immunohistochemistry, IHC-P immunohistochemistry-paraffin protocol, Recommended species species reactivity as provided by the antibody supplier (Hu human, Ms mouse, Rt rat, Dm Drosophila, Zf Zebra fish, Gp Guinea pig, Bt bat, Bo bovine, Do dog, Mo monkey, Ha hamster, Ho horse, and Ra rabbit), % reduction of signal average percent reduction of the fluorescence signal after incubation of human vascular smooth muscle cells with receptor-specific siRNA, as compared with cells after incubation with non-targeting siRNA observed a 72 % reduction of the flow cytometry signal after transfection of cells with ACKR3 siRNA when this antibody was employed. When a reduction in signal by 70 % or more is considered as a benchmark for excellent target selectivity in our assay, eight of the tested antibodies would be considered to show excellent selectivity. Nevertheless, the remaining four antibodies would still show at least good or sufficient selectivity to report alterations in the expression levels of their endogenous protein targets. Interestingly, anti-α 1A /sc1477 and anti-ACKR3/ab38089 have previously been reported to be non-specific, as assessed by Western blot experiments or immunohistochemistry with tissues from knockout mice (Jensen et al. 2009; Berahovich et al. 2010 ). Under our experimental conditions, however, both antibodies showed excellent selectivity, comparable or better than anti-ACKR3/mab42278 (clone 11G8).
In combination with previous observations that a β 3 -AR antibody was non-selective in Western blot experiments but selective when used for immunohistochemistry (Cernecka et al. 2014) , these data suggest that antibodies can display different degrees of selectivity in different assays, different species or tissues, and when different types of specimens, such cells, homogenates, or tissue sections, are being evaluated. This phenomenon is likely related to the fact that, depending on the application and experimental conditions, the probed epitopes can be linear or three-dimensional, completely exposed, and completely or partially masked by post-translational modifications. Vice versa, it may also be possible that an antibody that has been validated in tissues that lack the target gene does not show selectivity when tested in another tissue, species, or application.
In conclusion, we have validated 12 commercially available antibodies directed against GPCRs when employed for flow cytometry with hVSMC. The majority of these antibodies showed excellent selectivity for the endogenous GPCR target under our experimental conditions. Such antibody validation, however, is labor intensive and time consuming. Furthermore, the costs for siRNA reagents are high and may not be affordable for every research laboratory. As the antibodies are being sold for profit, we believe that the commercial antibody provider should share this burden and validate an antibody for the application and species for which it is marketed. This will likely reduce the risk for the individual investigator to waste the limited financial resources that are currently available to the majority of the scientific community. We strongly concur with the criteria proposed by Michel et al. and recommend confirmation of antibody selectivity under the specific experimental conditions for which the antibodies are being employed. While this will improve scientific rigor, it will also increase costs for labor and supplies. We share the opinion that requests for additional funding for antibody validation should be Cells (human vascular smooth muscle cells) were incubated with nontargeting siRNA or siRNA targeting α 1 -AR subtypes and then analyzed by flow cytometry utilizing the antibodies listed. Data are mean ± standard deviation, n = 3 %RFU relative fluorescence units in percent of the fluorescence units measured after incubation of cells with non-targeting siRNA proposed in research funding applications and be honored by the peer-reviewers and funding agencies.
